Match tier
Listed
Presence
Current · Arkansas
Last published
2026
Sources
OpenAlex · ORCID
Refreshed
2026-10-03
Valentina K. Todorova
Assistant Professor
Also affiliated: Bulgarian Academy of Sciences (1993–2000); University of Arkansas Medical Center (2009–2017); Institute of Molecular Biology (2000); Central Arkansas Veterans Healthcare System (2008–2024); University of Glasgow (1995)
Internal Med, College of Medicine
18 h-index
39 pubs
827 cited
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Valentina K. Todorova's research focuses on the mechanisms of cardiotoxicity induced by chemotherapy agents, particularly doxorubicin, in breast cancer patients and animal models. She has investigated the role of glutamine in mitigating this toxicity, with studies examining its effects on tumor glutathione levels and apoptosis-related proteins in rats. Todorova also explores potential predictive biomarkers for doxorubicin-induced cardiotoxicity, including immune response proteins, inflammation markers, and microRNAs identified through transcriptome profiling of peripheral blood cells. Her work has involved collaborations with researchers from the University of Arkansas for Medical Sciences and Ouachita Baptist University. Todorova has published 40 papers, with an h-index of 18 and over 825 citations.
Metrics
- h-index: 18
- Publications: 39
- Citations: 827
Positions
-
Assistant Professor publications 2003–2026University of Arkansas for Medical Sciences Internal Med, College of Medicine Institutional directory
Selected Publications
-
Baseline proteomic biomarkers for predicting chemotherapy-induced cardiotoxicity in breast cancer patients (2026)
-
Neutrophil Biomarkers Can Predict Cardiotoxicity of Anthracyclines in Breast Cancer (2024)
-
RNA sequencing of formalin fixed paraffin-embedded heart tissue provides transcriptomic information about chemotherapy-induced cardiotoxicity (2024)
-
Abstract 3625: Metabolic phenotypes of doxorubicin-induced cardiotoxicity in breast cancer patients (2024)
-
Review of: "Effect of neutrophil-to-lymphocyte ratio and vitamin D3 levels on the pathological complete response after neoadjuvant treatment in TNBC and HER2-positive early breast cancer – results of a prospective study" (2023)
-
Exosomal MicroRNA and Protein Profiles of Hepatitis B Virus-Related Hepatocellular Carcinoma Cells (2023)
-
Circulating Exosomal microRNAs as Predictive Biomarkers of Neoadjuvant Chemotherapy Response in Breast Cancer (2022)
-
Subclinical doxorubicin-induced cardiotoxicity update: role of neutrophils and endothelium. (2021)
-
Biomarkers of inflammation, hypercoagulability and endothelial injury predict early asymptomatic doxorubicin-induced cardiotoxicity in breast cancer patients. (2020)
-
Abstract LB-174: Genome-wide DNA methylation signatures predict the early asymptomatic doxorubicin-induced cardiotoxicity in breast cancer (2020)
-
Abstract LB-341: Circulating exosomal microRNAs as promising early biomarkers of neoadjuvant chemotherapy response in breast cancer (2020)
-
Genome-wide DNA methylation signatures to predict pathologic complete response from combined neoadjuvant chemotherapy with bevacizumab in breast cancer (2020)
-
Dantrolene Attenuates Cardiotoxicity of Doxorubicin Without Reducing its Antitumor Efficacy in a Breast Cancer Model (2020)
-
Abstract 815: Genome-wide DNA methylation signatures to predict pathologic complete response from combined neoadjuvant chemotherapy with bevacizumab in breast cancer (2019)
-
Abstract 815: Genome-wide DNA methylation signatures to predict pathologic complete response from combined neoadjuvant chemotherapy with bevacizumab in breast cancer (2019)
Grants & Funding
As listed on this researcher's institutional profile.
- Center for Studies of Host Response to Cancer Therapy NIH Co-Investigator
- Advancing Breast Cancer Treatment through Suppression of Chemo-Resistance UAMS Executive Breast Committee Principal Investigator
- Arkansas Claude Pepper Older Americans Independence Center at UAMS NIH Co-Investigator
- TCIA Sustainment and Scalability - Platforms for Quantitative Imaging Informatics in Precision Medicine NIH Co-Investigator
- Dietary glutamine and protection against doxorubicin and cyclophosphamide toxicity Susan G. Komen for the Cure Principal Investigator
Collaboration Network
Top Collaborators
Issam Makhoul
Arkansas Cardiology
23 shared publications
In database
- Immune response proteins as predictive biomarkers of doxorubicin-induced cardiotoxicity in breast cancer patients
- Biomarkers of inflammation, hypercoagulability and endothelial injury predict early asymptomatic doxorubicin-induced cardiotoxicity in breast cancer patients.
- Transcriptome Profiling of Peripheral Blood Cells Identifies Potential Biomarkers for Doxorubicin Cardiotoxicity in a Rat Model
- Circulating Exosomal microRNAs as Predictive Biomarkers of Neoadjuvant Chemotherapy Response in Breast Cancer
- Circulating miRNA Profiles of Doxorubicin-induced Cardiotoxicity in Breast Cancer Patients.
Showing 5 of 23 shared publications
Jeanne Y. Wei
University of Arkansas for Medical Sciences
14 shared publications
In database
- Immune response proteins as predictive biomarkers of doxorubicin-induced cardiotoxicity in breast cancer patients
- Biomarkers of inflammation, hypercoagulability and endothelial injury predict early asymptomatic doxorubicin-induced cardiotoxicity in breast cancer patients.
- Transcriptome Profiling of Peripheral Blood Cells Identifies Potential Biomarkers for Doxorubicin Cardiotoxicity in a Rat Model
- Circulating miRNA Profiles of Doxorubicin-induced Cardiotoxicity in Breast Cancer Patients.
- Dantrolene Attenuates Cardiotoxicity of Doxorubicin Without Reducing its Antitumor Efficacy in a Breast Cancer Model
Showing 5 of 14 shared publications
V. Suzanne Klimberg
University of Arkansas for Medical Sciences (US)
11 shared publications
- Tamoxifen and raloxifene suppress the proliferation of estrogen receptor-negative cells through inhibition of glutamine uptake
- Effect of dietary glutamine on tumor glutathione levels and apoptosis-related proteins in DMBA-induced breast cancer of rats
- Oral Glutamine Protects against Acute Doxorubicin-Induced Cardiotoxicity of Tumor-Bearing Rats
- Transcriptome Profiling of Peripheral Blood Cells Identifies Potential Biomarkers for Doxorubicin Cardiotoxicity in a Rat Model
- Circulating miRNA Profiles of Doxorubicin-induced Cardiotoxicity in Breast Cancer Patients.
Showing 5 of 11 shared publications
Eric R. Siegel
University of Arkansas for Medical Sciences
8 shared publications
In database
- Dantrolene Attenuates Cardiotoxicity of Doxorubicin Without Reducing its Antitumor Efficacy in a Breast Cancer Model
- Germline Genetic Variants in TEK, ANGPT1, ANGPT2, MMP9, FGF2 and VEGFA Are Associated with Pathologic Complete Response to Bevacizumab in Breast Cancer Patients
- Biomarkers for Presymptomatic Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients
- Genome-wide DNA methylation signatures to predict pathologic complete response from combined neoadjuvant chemotherapy with bevacizumab in breast cancer
- Reducing doxorubicin cardiotoxicity in rats with mammary tumors by dantrolene.
Showing 5 of 8 shared publications
Yihong Kaufmann
University of Arkansas for Medical Sciences
7 shared publications
In database
- Tamoxifen and raloxifene suppress the proliferation of estrogen receptor-negative cells through inhibition of glutamine uptake
- Effect of dietary glutamine on tumor glutathione levels and apoptosis-related proteins in DMBA-induced breast cancer of rats
- Oral Glutamine Protects against Acute Doxorubicin-Induced Cardiotoxicity of Tumor-Bearing Rats
- Dantrolene Attenuates Cardiotoxicity of Doxorubicin Without Reducing its Antitumor Efficacy in a Breast Cancer Model
- Glutamine regulation of doxorubicin accumulation in hearts versus tumors in experimental rats
Showing 5 of 7 shared publications
Ping-Ching Hsu
University of Arkansas for Medical Sciences
6 shared publications
In database
- Biomarkers of inflammation, hypercoagulability and endothelial injury predict early asymptomatic doxorubicin-induced cardiotoxicity in breast cancer patients.
- Genome-wide DNA methylation signatures to predict pathologic complete response from combined neoadjuvant chemotherapy with bevacizumab in breast cancer
- Abstract 815: Genome-wide DNA methylation signatures to predict pathologic complete response from combined neoadjuvant chemotherapy with bevacizumab in breast cancer
- Abstract LB-174: Genome-wide DNA methylation signatures predict the early asymptomatic doxorubicin-induced cardiotoxicity in breast cancer
- Abstract 815: Genome-wide DNA methylation signatures to predict pathologic complete response from combined neoadjuvant chemotherapy with bevacizumab in breast cancer
Showing 5 of 6 shared publications
Shaoke Luo
University of Arkansas for Medical Sciences (US)
4 shared publications
- Tamoxifen and raloxifene suppress the proliferation of estrogen receptor-negative cells through inhibition of glutamine uptake
- Effect of dietary glutamine on tumor glutathione levels and apoptosis-related proteins in DMBA-induced breast cancer of rats
- Modulation of p53 and c-myc in DMBA-Induced Mammary Tumors by Oral Glutamine
- Glutamine Affects Glutathione Recycling Enzymes in a DMBA-Induced Breast Cancer Model
Marjorie L. Beggs
University of Arkansas for Medical Sciences (US)
4 shared publications
- Transcriptome Profiling of Peripheral Blood Cells Identifies Potential Biomarkers for Doxorubicin Cardiotoxicity in a Rat Model
- Biomarkers for Presymptomatic Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients
- Correction: Transcriptome Profiling of Peripheral Blood Cells Identifies Potential Biomarkers for Doxorubicin Cardiotoxicity in a Rat Model
- Role of neutrophils in the early presymptomatic stages of doxorubicin cardiotoxicity in breast cancer.
Ishwori Dhakal
University of Arkansas for Medical Sciences (US)
4 shared publications
- Transcriptome Profiling of Peripheral Blood Cells Identifies Potential Biomarkers for Doxorubicin Cardiotoxicity in a Rat Model
- Polymorphic Variations Associated With Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients
- Germline Genetic Variants in TEK, ANGPT1, ANGPT2, MMP9, FGF2 and VEGFA Are Associated with Pathologic Complete Response to Bevacizumab in Breast Cancer Patients
- Correction: Transcriptome Profiling of Peripheral Blood Cells Identifies Potential Biomarkers for Doxorubicin Cardiotoxicity in a Rat Model
Annjanette Stone
Central Arkansas Veterans Healthcare System (US)
4 shared publications
- Polymorphic Variations Associated With Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients
- Biomarkers for Presymptomatic Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients
- Neutrophil Biomarkers Can Predict Cardiotoxicity of Anthracyclines in Breast Cancer
- Abstract LB-174: Genome-wide DNA methylation signatures predict the early asymptomatic doxorubicin-induced cardiotoxicity in breast cancer
Aaron Owen
University of Arkansas for Medical Sciences
4 shared publications
In database
- Dantrolene Attenuates Cardiotoxicity of Doxorubicin Without Reducing its Antitumor Efficacy in a Breast Cancer Model
- Polymorphic Variations Associated With Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients
- Biomarkers for Presymptomatic Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients
- Reducing doxorubicin cardiotoxicity in rats with mammary tumors by dantrolene.
Susan Kadlubar
University of Arkansas for Medical Sciences
4 shared publications
In database
- Germline Genetic Variants in TEK, ANGPT1, ANGPT2, MMP9, FGF2 and VEGFA Are Associated with Pathologic Complete Response to Bevacizumab in Breast Cancer Patients
- Genome-wide DNA methylation signatures to predict pathologic complete response from combined neoadjuvant chemotherapy with bevacizumab in breast cancer
- Abstract 815: Genome-wide DNA methylation signatures to predict pathologic complete response from combined neoadjuvant chemotherapy with bevacizumab in breast cancer
- Abstract 815: Genome-wide DNA methylation signatures to predict pathologic complete response from combined neoadjuvant chemotherapy with bevacizumab in breast cancer
Leah Hennings
University of Arkansas for Medical Sciences (US)
3 shared publications
- Oral Glutamine Protects against Acute Doxorubicin-Induced Cardiotoxicity of Tumor-Bearing Rats
- Immunomodulatory Effects of Radiofrequency Ablation in a Breast Cancer Model
- Glutamine regulation of doxorubicin accumulation in hearts versus tumors in experimental rats
Weleetka Carter
Central Arkansas Veterans Healthcare System (US)
3 shared publications
- Polymorphic Variations Associated With Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients
- Biomarkers for Presymptomatic Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients
- Abstract LB-174: Genome-wide DNA methylation signatures predict the early asymptomatic doxorubicin-induced cardiotoxicity in breast cancer
Robert J. Griffin
University of Arkansas for Medical Sciences
3 shared publications
In database
- Germline Genetic Variants in TEK, ANGPT1, ANGPT2, MMP9, FGF2 and VEGFA Are Associated with Pathologic Complete Response to Bevacizumab in Breast Cancer Patients
- Tumor-endothelial cell interaction in an experimental model of human hepatocellular carcinoma
- Exosomal MicroRNA and Protein Profiles of Hepatitis B Virus-Related Hepatocellular Carcinoma Cells
Similar Researchers
Based on overlapping research topics
Richard D. Beger
National Center for Toxicological Research
Pharmacological Effects and Toxicity Studies
Disease Models, Animal
Diet and metabolism studies
Hee Seop Lee
University of Arkansas at Fayetteville
Pharmacological Effects and Toxicity Studies
Immune Response and Inflammation
Disease Models, Animal
Yifan Zhang
National Center for Toxicological Research
Pharmacological Effects and Toxicity Studies
Cancer Treatment and Pharmacology
Immune Response and Inflammation
Shi Jesse Liu
University of Arkansas for Medical Sciences
Pharmacological Effects and Toxicity Studies
Immune Response and Inflammation
Disease Models, Animal
Jaclyn R. Daniels
National Center for Toxicological Research
Pharmacological Effects and Toxicity Studies
Cancer Treatment and Pharmacology
Immune Response and Inflammation
Pravin Parajuli
National Center for Toxicological Research
Pharmacological Effects and Toxicity Studies
Cancer Treatment and Pharmacology
Immune Response and Inflammation